Investigadores han rastreado los orígenes del virus de la hepatitis B al analizar restos humanos de la Edad del Bronce, del Hierro y Media
...
Por lo Qué Hasta la Obtención de los Resultados Completos ... Más la Elaboración del Dossier ... Más la Evaluación de las Agencias ... Nos Podemos Ir al 2027 .
12 mayo 2018
Next Generation Antibody Therapeutics Market is Expected to Expand US$ 6.75 Bn in 2022 .
May 11, 2018 // rahul // Business & Money.
According to a new market report published by Persistence Market Research “Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022”, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.
Next-generation antibody therapeutics refers to improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Advancements in monoclonal antibody technologies have led to the development of next-generation therapeutic antibodies with reduced functional size, greater bifunctional properties, and low immunogenicity. Next-generation antibody-based therapeutics enhances existing properties of therapeutic antibodies for the treatment of various medical conditions such as cancer, infectious diseases, and autoimmune diseases.
...
According to a new market report published by Persistence Market Research “Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022”, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.
Next-generation antibody therapeutics refers to improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Advancements in monoclonal antibody technologies have led to the development of next-generation therapeutic antibodies with reduced functional size, greater bifunctional properties, and low immunogenicity. Next-generation antibody-based therapeutics enhances existing properties of therapeutic antibodies for the treatment of various medical conditions such as cancer, infectious diseases, and autoimmune diseases.
...
A focus on partnerships at Hutch/Merck summit .
Research on the immune system aims to stop infectious diseases and cancer.
May 11, 2018 . By Sabin Russell / Fred Hutch News Service.
Niki Robinson, Fred Hutch's vice president of Business Development & Strategy (back to camera), greets Fred Hutch President and Director Dr. Gary Gilliland and Merck's Darla Hazuda ad Alex Szidon at the beginning of the Infectious Disease Summit.
Niki Robinson, Fred Hutch's vice president of Business Development & Strategy (back to camera), greets Fred Hutch President and Director Dr. Gary Gilliland and Merck's Darla Hazuda ad Alex Szidon at the beginning of the Infectious Disease Summit. ...
May 11, 2018 . By Sabin Russell / Fred Hutch News Service.
Niki Robinson, Fred Hutch's vice president of Business Development & Strategy (back to camera), greets Fred Hutch President and Director Dr. Gary Gilliland and Merck's Darla Hazuda ad Alex Szidon at the beginning of the Infectious Disease Summit.
Niki Robinson, Fred Hutch's vice president of Business Development & Strategy (back to camera), greets Fred Hutch President and Director Dr. Gary Gilliland and Merck's Darla Hazuda ad Alex Szidon at the beginning of the Infectious Disease Summit. ...
Suscribirse a:
Entradas (Atom)